Sotera Health (SHC)
Health Care · medical sterilization and testing services · NASDAQ
A global provider of essential sterilization and lab testing services for the healthcare industry.
What Sotera Health does
Sotera Health provides mission-critical sterilization and lab testing services to the healthcare industry. The company offers sterilization solutions for medical devices and pharmaceutical products, as well as analytical and advisory services to ensure compliance with global regulatory standards.
Themes: medical device sterilization, healthcare supply chain safety, pharmaceutical testing services
Fundamentals
- Price$19.57 as of 2026-08-21 close
- Market cap$5.6B as of 2026-08-21
- 1-year return+22.8% 2025-08-21 close $15.93 → 2026-08-21 close $19.57
- P/E46.08 as of 2026-08-24
- Net margin+9.9% as of 2026-08-24
- Gross margin+55.3% as of 2026-08-24
- ROE+20.6% as of 2026-08-24
- Debt / equity3.59 as of 2026-08-24
- Revenue growth (YoY)+7.4% as of 2026-08-24
- Revenue CAGR (3y)+5.1% SEC XBRL
- Beta1.86 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How SHC compares in its sector
- price-to-earnings ratiotop 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
SHC is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
56.2 #402 of 1,704 scored · #77 of 240 in Health Care
Trend 71st: a strong uptrend, with buyers in control; catalysts 68th: analysts have raised their average price target by 1.5% since the prior reading; weakest is setup 26th: over the past year its closes ranged, and it has retraced essentially none of its move over the past year — 0% of it.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which SHC reported a dividend payment is FY2019, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2019 ratio would not describe SHC today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2019) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How Sotera Health looks technically
Sotera Health (SHC) is trading 17.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 25 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 68, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It just made a new 20-day high, pushing above its recent trading range. It is 1.4% below its 52-week high (its highest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 17.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +17.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $17.74 | $17.74 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $16.66 | $16.66 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 19.788. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 25 trading days ago — a "golden cross", a bullish long-term signal | 25 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with buyers in control | 29.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 68, neither overbought (above 70) nor oversold (below 30) | 68.3 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($17.83 to $19.79) — its "stochastic" reading is 89 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 88.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $19.85 | $19.85 |
|---|---|---|
| From the 52-week high | it is 1.4% below its 52-week high (its highest price of the past year) | -1.4% |
| Above the 52-week low | it is 49.5% above its 52-week low (its lowest price of the past year) | +49.5% |
| Below the 52-week high | it is 1.4% below its highest point of the past year | 1.4% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $30.38 (set on 2021-03-15) | $30.38 |
| Given back of the 52-week move | over the past year its closes ranged ($13.13 to $19.57), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $15.38 to $15.59. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 35.6% below its all-time high | -35.6% |
| Nearest price level | it is trading 1.3% below a resistance level at $19.82 — a price it turned at twice since 2026-01-09, most recently on 2026-08-07. Since 2024-08-21 it has 15 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.3% |
| All-time low | its lowest closing price on record is $5.78 (set on 2022-11-09) | $5.78 |
| Above the all-time low | it is 238.6% above its all-time low | +238.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 50th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5209 between its high and its low — about 2.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5209 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $17.23 and $19.77 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $17.23 – $18.50 – $19.77 |
| Typical daily range (% of price) | its price moves about 2.7% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.7% |
| Stretch from the 200-day average | it is trading 5.6 daily ranges above its 200-day average price (17.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.76× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.5% since the prior reading | +1.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.4% |
|---|---|---|
| Open gap | it gapped 3.2% above the previous close 11 sessions ago and has not traded back through the level it left behind at 17.98 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.2% |
| Gap filled | a 4.6% gap up opened on 2026-08-07 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 10 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +5.73% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 10.1 percentage points (the stock gained 12.5% while the market gained 2.3%) | +10.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 21.5 percentage points (the stock gained 24.6% while the market gained 3.1%) | +21.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 0.8 percentage points (the stock gained 11.9% while the market gained 11.1%) | +0.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 2.4 percentage points (the stock gained 22.8% while the market gained 20.5%) | +2.4% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 12% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.5% of the share price. | +12.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 19% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $16.42 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +19.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $18.96 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +3.2% |
Price levels it has turned at before
SHC last closed at $19.57 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $19.82 | Resistance | 1.3% above the last close | turned there twice · 2026-01-09 to 2026-08-07 |
| $17.80 | Support | 9.0% below the last close | turned there three times · 2025-11-04 to 2026-02-24 |
| $17.02 | Support | 13.0% below the last close | turned there three times · 2024-09-09 to 2026-07-21 |
| $16.55 | Support | 15.4% below the last close | turned there 8 times · 2024-11-11 to 2026-06-12 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $19.79.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 6 trading days, since 2026-08-14.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Near the 52-week high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$22.72 range $18.00 – $25.00; median $22.50
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SHC
- Consensus EPS estimate$0.2685 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Litigation related to the use and emissions of ethylene oxide (EO) from sterilization facilities.","Risks associated with the handling, transport, and storage of hazardous materials like EO and Cobalt-60.","Significant debt leverage that may restrict operational flexibility and financial operations."]
What changed in the latest 10-Q
AI-assisted comparison of SHC's 10-Q filed 2026-05-05 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 2025 Form 10-K; older filing references 2024 Form 10-K
- Newer filing reports Q1 2026 results (three months ended March 31, 2026); older filing reports Q3 2025 results (three months ended September 30, 2025)
- Newer filing reports net revenues of $280.0 million for Q1 2026; older filing reports $311.3 million for Q3 2025
- Newer filing reports net income of $26.6 million for Q1 2026; older filing reports $48.4 million for Q3 2025
- Newer filing reports Adjusted Net Income of $52.4 million and Adjusted EBITDA of $134.7 million for Q1 2026; older filing reports $75.3 million and $164.2 million respectively for Q3 2025
- Newer filing notes that foreign currency exchange rates had unfavorable $3.8 million impact to cost of service revenues
- Newer filing states service revenue growth was driven by favorable pricing in Sterigenics and Nelson Labs segments with volume decline in Nelson Labs
- Newer filing attributes product revenue increase primarily to Co-60 harvest schedule timing at Nordion
- Removed:
- Older filing reference to nine months ended September 30, 2025 results ($860.2 million revenues, $43.1 million net income, $170.4 million Adjusted Net Income, $436.8 million Adjusted EBITDA) not present in newer filing
- Older filing description of service revenue growth including core lab testing service volume/mix increases in Nelson Labs segment not present in newer filing
- Older filing mention of decline in expert advisory services revenue in Nelson Labs segment not present in newer filing's Q1 2026 discussion
- Older filing reference to amortization of intangible assets fully amortized as of December 31, 2024 not present in newer filing
- Reworded:
- Newer filing states cost of revenues accounted for 47.5% of consolidated net revenues (Q1 2026) versus older filing's 43.0% (Q3 2025)
- Newer filing attributes cost of service revenue increases to 'higher employee compensation costs, depreciation from capital assets recently placed into service, and increase in direct material costs driven mainly by higher volumes' versus older filing's attribution to 'inflation impacting direct materials, energy and employee compensation costs'
- Newer filing notes foreign currency exchange rates had 'unfavorable impact' to both cost of service and cost of product revenues, with specific quantification for service; older filing does not quantify foreign currency impacts
- Newer filing describes product revenue increase driven by 'favorable volume and mix at Nordion, which was primarily attributable to Co-60 harvest schedule timing' versus older filing's simpler attribution to 'timing of reactor harvest schedules'
- Notes:
- The two filings report results for different fiscal periods (Q1 2026 vs Q3 2025), which fundamentally affects all comparative metrics and narrative explanations
- Newer filing text appears truncated mid-sentence ('SG&A Expenses increased $5'), limiting assessment of completeness of that section
- Direct year-over-year comparisons are made within each filing (2026 vs 2025 for newer; 2025 vs 2024 for older), so the narrative changes partly reflect different prior-year comparisons rather than changes in the company's actual performance
Risk Factors
- Added:
- Added risk factor: 'the risks associated with the introduction of artificial intelligence ("AI") technology' (filed 2026-05-05)
- Added risk factor: 'the influence that certain investment funds and entities affiliated with Warburg Pincus and GTCR, which we refer to collectively as the "Sponsors," continue to have over us' (filed 2026-05-05)
- Removed:
- Removed phrase 'or preferences' from environmental, health and safety regulations risk factor (filed 2025-11-04)
- Removed phrase 'and general economic, social and business conditions' from environmental, health and safety regulations risk factor (filed 2025-11-04)
- Removed specific facility references 'in California, Georgia, Illinois and New Mexico' from EO litigation risk factor (filed 2025-11-04)
- Removed risk factor: 'our ability to satisfy the conditions for settlement of the EO claims related to our former facility in Willowbrook, Illinois' (filed 2025-11-04)
- Removed phrase 'the impact of the U.S. federal government shutdown' from business continuity hazards risk factor (filed 2025-11-04)
- Reworded:
- Changed 'sanctions against Russia by the United States, Canada, United Kingdom and/or the European Union' to 'sanctions against Russia by the United States, Canada, the United Kingdom and/or the European Union' (added 'the' before United Kingdom) (filed 2026-05-05)
- Changed 'or sanctions by Russia against those countries' added as new clause in geopolitical risk (filed 2026-05-05)
- Changed 'our other direct materials, services and supplies' to explicitly reference geopolitical instability impact (filed 2026-05-05)
- Changed 'litigation related to the use, emissions and releases of EO from our current and former EO sterilization facilities' to broader language without specific facility names (filed 2026-05-05)
- Changed 'federal government shutdowns' (plural) replacing 'the impact of the U.S. federal government shutdown' (filed 2026-05-05)
- Changed 'cybersecurity incidents, unauthorized data disclosures, and our dependence on information technology ("IT") systems' to add parenthetical abbreviation for IT (filed 2026-05-05)
- Changed 'our reliance on intellectual property rights' to 'our reliance on intellectual property rights' with 'rights' added (filed 2026-05-05)
- Changed 'our significant degree of leverage and how this leverage could adversely affect' to replace 'our significant leverage and how this significant leverage could adversely affect' (filed 2025-11-04)
- Changed 'limit our ability to react to challenges facing our Company' to replace 'limit our ability to react to challenges confronting our Company' (filed 2026-05-05)
- Reference changed from '2025 10-K' and 'December 31, 2025' to '2024 Form 10-K' and 'December 31, 2024' (reflects updated fiscal year reference) (filed 2026-05-05)
- Notes:
- The financial statements sections shown are from different balance sheet dates (March 31, 2026 vs. September 30, 2025) and are not directly comparable as risk factor changes
- Page number references changed between filings (Item 1A moved from page 47 to page 34), indicating document restructuring
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($3M) — 1 selling insider
- Last 90 days0 buys · 1 sell ($3M) — 1 selling insider
- Last 180 days0 buys · 4 sells ($776M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-07. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SHC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding SHC as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 29,489,655
- Reported value $422,881,653
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SHC had 14,381,320 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SHC had 5.04% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.8 days to cover at the same settlement.
- Reported short interest (shares) 14,381,320
- Short interest (% of shares outstanding) 5.04%
- Prior settlement (shares) 15,837,315
- Reported change -9.19%
- Days to cover (reported) 4.8
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Steris (STE)
- Charles River Laboratories (CRL)
- Eurofins Scientific
- Nelson Labs
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SHC vs…
Frequently asked questions
What does Sotera Health (SHC) do?
Sotera Health provides mission-critical sterilization and lab testing services to the healthcare industry. The company offers sterilization solutions for medical devices and pharmaceutical products, as well as analytical and advisory services to ensure compliance with global regulatory standards.
What sector is Sotera Health (SHC) in?
Sotera Health (SHC) is classified in the Health Care sector. Its industry is medical sterilization and testing services. It trades on NASDAQ.
Who are Sotera Health's (SHC) competitors?
Notable peers of Sotera Health (SHC) include Steris, Charles River Laboratories, Eurofins Scientific and Nelson Labs. This peer set is informational only — not financial advice.
Is Sotera Health (SHC) overbought or oversold right now?
Sotera Health (SHC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 68, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SHC come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.